Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Well Duh!

<< Previous

Bullboard Posts

Next >>

Comment by davgroon May 27, 2022 4:06pm

119 Views

Post# 34713303

RE:Well Duh!

Duster340 wrote: it is mcwhirters last post on antibe, this is the antbe bullboard so yeah it is relevant. just to refresh some memories of roberts thoughts on the company

You really are trying too hard Dumpster.

You are now posting old market research and grandiose analyst target prices. Are you now long ATE. Do you all of a sudden see positive momentum for ATE's stock price ?

Unfortunately your posts lack sincerity. Are you talking out of both sides of your mouth ? Just a month ago you posted the following which speaks for itself. BUSTED !!

Duster340 - (4/28/2022 9:30:16 AM) wrote: ATE is going nowhere. they have not proven anything yet. only positive results in the lab or massive insider buying like the mangement over at lyra did will convince shareholders that they have something. so for now canaccord has got it wright.

Antibe Therapeutics downgraded to Hold from Speculative Buy at Canaccord Canaccord Genuity analyst Tania Gonsalves downgraded Antibe Therapeutics to Hold from Speculative Buy with a price target of C$1.50, down from C$5. The company is shifting its focus from osteoarthritis to post-operative pain, says the analyst, who downgraded the shares after removing otenaproxesul from the valuation. The outlook for Antibe's osteoarthritis program is uncertain, Gonsalves tells investors in a research note.

Read more at:

https://thefly.com/n.php?id=3387765